RecruitingNCT06648317

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions


Sponsor

Peking University Cancer Hospital & Institute

Enrollment

20 participants

Start Date

Nov 21, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with lung lesions.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of PET/CT imaging scan using a radioactive tracer that targets a protein called Nectin-4, which is found on certain tumors. Researchers hope to use this scan to better identify and stage lung lesions (suspicious spots in the lungs). **You may be eligible if...** - You are 18–75 years old - You have at least one measurable tumor or lesion - Your doctor has recommended a PET/CT scan for cancer staging or diagnosis - You have normal heart function - You are expected to survive at least 12 weeks **You may NOT be eligible if...** - You have serious liver abnormalities - You are pregnant or of childbearing age and unwilling to use contraception - You are unable to follow study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFDG-PET

All study participants will undergo 18F-FDG PET/CT scan within 1 week


Locations(1)

Peking University Cancer Hospital & Institute

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06648317


Related Trials